Cardiac safety of ribociclib evaluated with 24-hour rhythm Holter electrocardiogram
Authors:
- Ayse Irem YasinAYAyse Irem Yasin
- Mahmut UluganyanMUMahmut Uluganyan
- Zehra Sucuoglu IsleyenZIZehra Sucuoglu Isleyen
- Atakan TopcuATAtakan Topcu
- Abdallah Tm ShbairASAbdallah Tm Shbair
- Melih SimsekMSMelih Simsek
- Mehmet BesirogluMBMehmet Besiroglu
- Yeliz Emine ErsoyYEYeliz Emine Ersoy
- Hacı Mehmet TürkHTHacı Mehmet Türk
- Mesut SekerMSMesut Seker
Open Access
- 8 July 2024
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (8) , 1-6
Abstract
Objective: We aimed to evaluate cardiac safety profile of ribociclib with 24-h rhythm Holter ECG. Material and method: Forty-two female metastatic breast cancer patients were included in the study. Rhythm Holter ECG was performed before starting treatment with ribociclib and after 3 months of the treatment initiation. Results: The mean age of the patients was 56.36 ± 12.73. 52.4% (n = 22) of the patients were using ribociclib in combination with fulvestrant and 47.6% (n = 20) with aromatase inhibitors. None of the patients developed cardiotoxicity. When the rhythm Holter results before and in third month of the treatment were compared, there was no statistically significant difference. Conclusion: This is the first study evaluating effects of ribociclib treatment on cardiac rhythm with Holter ECG. The findings suggested ribociclib has a low risk of causing early cardiotoxicity.Keywords
All Related Versions
Funding Information
- Bezmialem Vakif University
This publication has 21 references indexed in Scilit:
- Association of QTc Formula With the Clinical Management of Patients With CancerJAMA Oncology, 2022
- Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE studyAnnals of Oncology, 2021
- Increased risk of cardiac conduction abnormalities with ribociclib in patients with metastatic breast cancerHematology/Oncology and Stem Cell Therapy, 2021
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)Annals of Oncology, 2020
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2JAMA Oncology, 2020
- Breast cancerNature Reviews Disease Primers, 2019
- Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic ImplicationsBioDrugs, 2019
- MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancernpj Breast Cancer, 2019
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialThe Lancet Oncology, 2018
- Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugsCancer Treatment Reviews, 2018